<Disease><Name>DUCHENNE MUSCULAR DYSTROPHY</Name><Synonym>MUSCULAR DYSTROPHY, PSEUDOHYPERTROPHIC PROGRESSIVE, DUCHENNE AND BECKER TYPES; MUSCULAR DYSTROPHY, CHILDHOOD PSEUDOHYPER</Synonym><OMIM><Number>310200</Number><URL>http://omim.org/entry/310200</URL></OMIM><Orphanet><Number>98896</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=98896</URL></Orphanet><Protein><Number>Dystrophin, Latent-transforming growth factor beta-binding protein 4</Number><URL>http://www.uniprot.org/uniprot/?query=database:(type:mim%20310200)&amp;sort=score</URL></Protein><ExPASy><Number /><URL /></ExPASy><Gene>Xp21.2-p21.1</Gene><ICD>G71.0</ICD><Summary>rare (1:3000);X-linked recessive ;mutation in the gene encoding dystrophin</Summary><Symptoms><symtomp><id>2104</id><symptom>cardiomyopathy</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>3676</id><symptom>cardiomyopathy, dilated</symptom><category>CARDIOVASCULAR SYSTEM | CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>1883</id><symptom>ECG abnormalities [-]</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>2256</id><symptom>EMG abnormalities [-]</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>2214</id><symptom>hyporeflexia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1897</id><symptom>hypotonia</symptom><category>MUSCLES | NERVOUS SYSTEM</category></symtomp><symtomp><id>2424</id><symptom>mental retardation</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1787</id><symptom>muscle weakness</symptom><category>MUSCLES</category></symtomp><symtomp><id>1786</id><symptom>myopathy</symptom><category>MUSCLES</category></symtomp><symtomp><id>2507</id><symptom>onset, childhood / childhood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2143</id><symptom>respiratory insufficiency / respiratory failure</symptom><category>LUNG OR RESPIRATORY SYSTEM</category></symtomp></Symptoms><Metabolites><metabolite><id>694</id><name>Creatine kinase</name><specimen>serum</specimen><value>increased</value><min>40.00</min><max>400.00</max><unit>U/l</unit><age>child</age><method /><comment /></metabolite><metabolite><id>309</id><name>Creatine kinase</name><specimen>serum</specimen><value>increased</value><min>40.00</min><max>150.00</max><unit>U/l</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>308</id><name>Creatine kinase</name><specimen>serum</specimen><value>increased</value><min>60.00</min><max>400.00</max><unit>U/l</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>947</id><name>Creatine kinase</name><specimen>serum</specimen><value>increased</value><min>25.00</min><max>90.00</max><unit>U/l</unit><age>adult</age><method /><comment /></metabolite></Metabolites><Literatures><literature><id>5155</id><title>Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding </title><author>Aartsma-Rus A,</author><journal>Nucleic Acid Ther. 2017 Aug 10. do</journal><year>2017</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>4339</id><title>Pharmacological advances for treatment in Duchenne muscular dystrophy</title><author>Guiraud S,</author><journal>Curr Opin Pharmacol</journal><year>2017</year><book /><volume>34</volume><number>0</number><pages>36-48</pages><co_aut>Davies KE</co_aut></literature><literature><id>4341</id><title>The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review</title><author>Ryder S,</author><journal>Orphanet J Rare Dis</journal><year>2017</year><book /><volume>12</volume><number>1</number><pages>79</pages><co_aut>et al.</co_aut></literature><literature><id>4342</id><title>Progress toward Gene Therapy for Duchenne Muscular Dystrophy</title><author>Chamberlain JR,</author><journal>Mol Ther</journal><year>2017</year><book /><volume>25</volume><number>5</number><pages>1125-1131</pages><co_aut>Chamberlain JS</co_aut></literature><literature><id>4343</id><title>Eteplirsen in the treatment of Duchenne muscular dystrophy</title><author>Lim KR,</author><journal>Drug Des Devel Ther</journal><year>2017</year><book /><volume>11</volume><number>0</number><pages>533-545</pages><co_aut>Maruyama R, Yokota T</co_aut></literature><literature><id>3670</id><title>The importance of genetic diagnosis for Duchenne muscular dystrophy</title><author>Aartsma-Rus A,</author><journal>J Med Genet</journal><year>2016</year><book /><volume>53</volume><number>3</number><pages>145-153</pages><co_aut>Ginjaar IB, Bushby K</co_aut></literature><literature><id>4340</id><title>Genetic diagnosis as a tool for personalized treatment of Duchenne muscular dystrophy</title><author>Bello L,</author><journal>Acta Myol</journal><year>2016</year><book /><volume>35</volume><number>3</number><pages>122-127</pages><co_aut>Pegoraro E</co_aut></literature><literature><id>738</id><title>Gene therapy in Duchenne muscular dystrophy</title><author>Inui K</author><journal>Brain Dev</journal><year>1996</year><book /><volume>18</volume><number>5</number><pages>357-361</pages><co_aut>Okada S, Dickson G</co_aut></literature><literature><id>739</id><title>Evaluation of a program for long-term trteatment of Duchenne muscular dystrophy. Experience at the University Hospitals of Cleve</title><author>Vignos PJ</author><journal>J Bone Joint Surg Am</journal><year>1996</year><book /><volume>78</volume><number>0</number><pages>1844-1852</pages><co_aut>et al.</co_aut></literature><literature><id>741</id><title>Progress towards gene therapy for Duchenne muscular dystrophy</title><author>Hauser MA</author><journal>J Endocrinol</journal><year>1996</year><book /><volume>149</volume><number>0</number><pages>48109-</pages><co_aut>Chamberlain JS</co_aut></literature><literature><id>740</id><title>Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study</title><author>Reitter B</author><journal>Brain Dev Suppl</journal><year>1995</year><book /><volume>17</volume><number>0</number><pages>39-43</pages><co_aut /></literature><literature><id>742</id><title>Treatment of respiratory insufficiency in Duchennes muscular dystrophy: nasal ventilation in the initial stages</title><author>Rideau Y</author><journal>Monaldi Arch Chest Dis</journal><year>1995</year><book /><volume>50</volume><number>3</number><pages>235-238</pages><co_aut>et al.</co_aut></literature><literature><id>743</id><title>Deflazacort. A review of its pharmacological properties and therapeutic efficacy.</title><author>Markham A</author><journal>Drugs</journal><year>1995</year><book /><volume>50</volume><number>2</number><pages>317-333</pages><co_aut>Bryson HM</co_aut></literature><literature><id>744</id><title>A management trial for Duchenne cardiomyopathy</title><author>Ishikawa Y</author><journal>Am J Phys Med Rehabil</journal><year>1995</year><book /><volume>74</volume><number>0</number><pages>345-350</pages><co_aut>et al.</co_aut></literature></Literatures></Disease>